1 drug(s) with this reaction
1,292 total reports
Infective Pulmonary Exacerbation Of Cystic Fibrosis has been reported as an adverse reaction across 1 drug(s) manufactured by Abbvie Inc in the FDA Adverse Event Reporting System (FAERS) database. A combined total of 1,292 adverse event reports mention infective pulmonary exacerbation of cystic fibrosis in connection with Abbvie Inc products.
This page provides a breakdown of which Abbvie Inc drugs are most commonly associated with infective pulmonary exacerbation of cystic fibrosis, along with report counts and links to detailed safety analyses for each medication. Understanding which drugs from a single manufacturer share a common adverse reaction can help patients and healthcare providers identify potential class-wide safety patterns.
The following Abbvie Inc drugs have infective pulmonary exacerbation of cystic fibrosis listed in their FDA adverse event reports, sorted by report count:
In addition to infective pulmonary exacerbation of cystic fibrosis, the following adverse reactions have been reported across Abbvie Inc's drug portfolio:
1 drug(s) manufactured by Abbvie Inc have infective pulmonary exacerbation of cystic fibrosis listed in their FDA adverse event reports: PANCRELIPASE.
There are a combined 1,292 reports of infective pulmonary exacerbation of cystic fibrosis across 1 Abbvie Inc drug(s) in the FDA adverse event database.